Cited by 38Cerebrovascular and genetic disordersDementia and Cognitive Impairment ResearchNeurological Disease Mechanisms and Treatments

Amyloid pathology and vascular risk are associated with distinct patterns of cerebral white matter hyperintensities: A multicenter study in 3132 memory clinic patients

Open access
Biesbroek, J. Matthijs, Coenen, Mirthe, DeCarli, Charles, Fletcher, Evan M., Maillard, Pauline M., Alzheimer's Disease Neuroimaging Initiative, Barkhof, Frederik, Barnes, Josephine +34 more·2024·Alzheimer's & Dementia

Abstract

INTRODUCTION: White matter hyperintensities (WMH) are associated with key dementia etiologies, in particular arteriolosclerosis and amyloid pathology. We aimed to identify WMH locations associated with vascular risk or cerebral amyloid‐β 1‐42 (Aβ42)‐positive status. METHODS: Individual patient data ( n = 3,132; mean age 71.5 ± 9 years; 49.3% female) from 11 memory clinic cohorts were harmonized. WMH volumes in 28 regions were related to a vascular risk compound score (VRCS) and Aß42 status (based on cerebrospinal fluid or amyloid positron emission tomography), correcting for age, sex, study site, and total WMH volume. RESULTS: VRCS was associated with WMH in anterior/superior corona radiata (B = 0.034/0.038, p < 0.001), external capsule (B = 0.052, p < 0.001), and middle cerebellar peduncle (B = 0.067, p < 0.001), and Aß42‐positive status with WMH in posterior thalamic radiation (B = 0.097, p < 0.001) and splenium (B = 0.103, p < 0.001). DISCUSSION: Vascular risk factors and Aß42 pathology have distinct signature WMH patterns. This regional vulnerability may incite future studies into how arteriolosclerosis and Aß42 pathology affect the brain's white matter. Highlights: Key dementia etiologies may be associated with specific patterns of white matter hyperintensities (WMH). We related WMH locations to vascular risk and cerebral Aβ42 status in 11 memory clinic cohorts. Aβ42 positive status was associated with posterior WMH in splenium and posterior thalamic radiation. Vascular risk was associated with anterior and infratentorial WMH. Amyloid pathology and vascular risk have distinct signature WMH patterns.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/alz.13765

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 59 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [34]Lee S, Viqar F, Zimmerman ME, et al. White matter hyperintensities are a core feature of Alzheimer's disease: evidence from the dominantly inherited Alzheimer network. Ann Neurol. 2016; 79: 929‐ 939. 27016429 PMC4884146

Cited by

Sorted by citations

Authors
Biesbroek, J. M., Coenen, M., DeCarli, C., Fletcher, E. M., Maillard, P. M., Initiative, A. D. N., Barkhof, F., Barnes, J., Benke, T., Chen, C. P. L. H., Dal‐Bianco, P., Dewenter, A., Duering, M., Enzinger, C., Ewers, M., Exalto, L. G., Franzmeier, N., Hilal, S., Hofer, E., Koek, H. L., Maier, A. B., McCreary, C. R., Papma, J. M., Paterson, R. W., Pijnenburg, Y. A. L., Rubinski, A., Schmidt, R., Schott, J. M., Slattery, C. F., Smith, E. E., Sudre, C. H., Steketee, R. M. E., Teunissen, C. E., van den Berg, E., van der Flier, W. M., Venketasubramanian, N., Venkatraghavan, V., Vernooij, M. W., Wolters, F. J., Xin, X., Kuijf, H. J., & Biessels, G. J.
Affiliations
  • University Medical Center Utrecht (NL)
  • University of California, Davis (US)
  • Amsterdam University Medical Centers (NL)
  • Innsbruck Medical University (AT)
  • National University of Singapore (SG)
  • LMU Klinikum (DE)
  • University of Basel (CH)
  • Medical University of Graz (AT)
  • University of Calgary (CA)
  • Erasmus MC (NL)
  • Amsterdam Neuroscience (NL)
  • UCL Queen Square Institute of Neurology (GB)
  • Alzheimer Center Erasmus MC Erasmus MC University Medical Center Rotterdam The Netherlands
  • Alzheimer Center Amsterdam Department of Neurology Amsterdam Neuroscience Vrije Universiteit Amsterdam Amsterdam UMC Amsterdam The Netherlands
  • Department of Pharmacology Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore
Corresponding author
Biesbroek, J. Matthijs
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2024-03-13
Volume
20
Issue
4
Pages
2980-2989
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W4392761707
Cited by
38
References
59
Citations by year
2026: 12 · 2025: 21 · 2024: 5
FWCI
10.17
Type
journal article
Language
en
Open access
Locations
  • Alzheimer s & Dementia (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
  • VU Research Portal (publishedVersion, cc-by)
  • UCL Discovery (University College London) (submittedVersion, cc-by)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
Funders
  • Alzheimer's Disease Neuroimaging Initiative
  • National Institutes of Health (U01 AG024904)
  • U.S. Department of Defense (W81XWH‐12‐2‐0012)
  • National Institute on Aging
  • National Institute of Biomedical Imaging and Bioengineering
  • AbbVie
  • Alzheimer's Association
  • Alzheimer's Drug Discovery Foundation
  • BioClinica
  • Biogen
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Alzheimer Nederland
  • Austrian Science Fund (KLI523, P30134, I2889‐B31)
Topics
  • Health Sciences › Medicine › Neurology › Cerebrovascular and genetic disorders
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
white matter hyperintensities, amyloid-beta 42
MeSH terms
Aged, Aged, 80 and over, Dementia, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Amyloid beta-Peptides, Arteriolosclerosis, White Matter

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review